Phase II trial of concomitant hyperfractionated-accelerated radiotherapy (HART) with cisplatin (Cis) plus cetuximab (Cet) for locoregionally advanced inoperable squamous cell carcinoma of the head and neck (LA SCCHN): Feasibility and 2-year OS.

Thomas Kuhnt(Leipzig University), Juergen Dunst(Martin Luther University Halle-Wittenberg), Rita Engenhart- Cabilic(Philipps University of Marburg), Peter Hass, Michael Richter, Frank Sieker(Martin Luther University Halle-Wittenberg), A. Pirnasch(University of Rostock), Matthias Hautmann, Andreas Schreiber(University of South Australia), Kathrin Dellas(Martin Luther University Halle-Wittenberg)
Journal of Clinical Oncology
May 20, 2013
Cited by 3


Related Papers